Wells Fargo & Company MN Has $626,000 Stake in Autolus Therapeutics plc (NASDAQ:AUTL)

Wells Fargo & Company MN cut its position in Autolus Therapeutics plc (NASDAQ:AUTL) by 31.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 266,315 shares of the company’s stock after selling 119,558 shares during the quarter. Wells Fargo & Company MN’s holdings in Autolus Therapeutics were worth $626,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Daiwa Securities Group Inc. raised its position in Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock valued at $56,000 after purchasing an additional 8,479 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Autolus Therapeutics by 21.2% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 82,411 shares of the company’s stock valued at $194,000 after purchasing an additional 14,432 shares during the last quarter. Dumont & Blake Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 4th quarter worth $35,000. Handelsbanken Fonder AB lifted its position in shares of Autolus Therapeutics by 30.9% during the 4th quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company’s stock worth $172,000 after buying an additional 17,300 shares during the last quarter. Finally, Arkadios Wealth Advisors acquired a new stake in Autolus Therapeutics in the fourth quarter valued at about $47,000. Institutional investors own 72.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AUTL shares. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, April 10th. Truist Financial dropped their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Finally, Wells Fargo & Company cut their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 21st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $9.32.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL opened at $1.35 on Friday. The stock’s 50-day moving average is $1.58 and its 200-day moving average is $2.37. Autolus Therapeutics plc has a 1-year low of $1.11 and a 1-year high of $5.00. The stock has a market cap of $359.23 million, a P/E ratio of -1.12 and a beta of 2.06.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. As a group, equities analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.